|
|
|
|
Fluorescence Microscopy Demonstrates Enhanced Targeting of Telavancin to the Division Septum of Staphylococcus aureus [Article]
The cellular binding patterns of fluorescent conjugates of telavancin and vancomycin were evaluated in Staphylococcus aureus using fluorescence microscopy and ratio imaging analysis.Telavancin showed enhanced binding at the division septum compared to ...
|
|
|
Comparative Activity of TR-700 (Torezolid) Against Staphylococcal Blood Isolates Collected in Spain [Article]
The in vitro activity of TR-700 (torezolid) was evaluated against a collection of 660 staphylococcal blood isolates.TR-700 showed excellent activity against all the staphylococci tested. The MIC 50 /MIC 90 values of TR-700, linezolid, daptomycin, and ...
|
|
|
Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists'...
|
|
|
Antibiotic Sensitivity Profiles Determined with an Escherichia coli Gene Knockout Collection: Generating an An
Antimicrobial Agents and Chemotherapy, April 2010, p.1393-1403, Vol. 54, No. 4 Copyright 2010, American Society for Microbiology. All Rights Reserved. , Anne Liu, Lillian Tran, Elinne Becket, Kim Lee, Laney Chinn, Eunice Park, Katherine Tran, and...
|
|
|
Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years
Cross-sectional study.Methods Minimal inhibitory concentration susceptibility profiles for 1230 S. aureus Ciprofloxacin resistance among corneal and conjunctival S. aureus Ciprofloxacin and levofloxacin resistance among methicillin-sensitive S. aureus...
|
|
|
MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
MRX-I Targets Multi-Drug Resistant Gram Positive Infections - HAYWARD, Calif.and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has...
|
|
|
MicuRx Pharmaceuticals Files IND in China for Antibiotic Drug Candidate MRX-I
-- MRX-I Targets Multi-Drug Resistant Gram Positive Infections -- HAYWARD, USA and SHANGHAI, China March 15, 2010 MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed...
|
|
|
Antiseptic Bath Cuts Infection in ICU
By Michael Smith, North American Correspondent, MedPage TodayPublished: March 18, 2010Reviewed by Emeritus Professor University of Pennsylvania School of Medicine and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner Action Points Explain to interested...
|
|
|
A Therapy's Effect on Overall Clinical Success is the Attribute That Most Influences Surveyed Infectious Disease Specialists' Prescribing Decisions in Treating Complicated Skin and Skin Structure Infections
WALTHAM, Mass., March 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences...
|
|
|
A Therapy's Effect on Overall Clinical Success is the Attribute That Most Influences Surveyed Infectious Disease Specialists' Prescribing Decisions in Treating Complicated Skin and Skin Structure Infections
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists'...
|
|
|
A Therapy's Effect on Overall Clinical Success is the Attribute That Most Influences Surveyed Infectious Disease Specialists' Prescribing Decisions in Treating Complicated Skin and Skin Structure Infections
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists'...
|
|
|
A Therapy's Effect on Overall Clinical Success is the Attribute That Most Influences Surveyed Infectious Disease Specialists' Prescribing Decisions in Treating Complicated Skin and Skin Structure Infections
See more news releases in: Publishing & Information Services, Health Care & Hospitals, Infection Control, Medical Pharmaceuticals, Pharmaceuticals, Surveys, Polls and Research Pfizer's Zyvox Will Retain Decision Resources' Clinical Gold Standard for...
|
|
|
A Therapy's Effect on Overall Clinical Success is the Attribute That Most Influences Surveyed Infect
ious Disease Specialists' Prescribing Decisions in Treating Complicated Skin and Skin Structure Infections Pfizer's Zyvox Will Retain Decision Resources' Clinical Gold Standard for Complicated Skin and Skin Structure Infections Through 2018, According to a New...
|
|
|
A Therapy's Effect on Overall Clinical Success is the Attribute That Most Influences Surveyed Infectious Disease Specialists' Prescribing Decisions in Treating Complicated Skin and Skin Structure Infections
Pfizer's Zyvox Will Retain Decision Resources' Clinical Gold Standard for Complicated Skin and Skin Structure Infections Through 2018, According to a New Report from Decision Resources WALTHAM, Mass., March 17 /PRNewswire/ -- Decision Resources, one of the...
|
|
|
MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
MRX-I Targets Multi-Drug Resistant Gram Positive Infections HAYWARD, CA, USA and SHANGHAI, CHINA | March 15, 2010 | MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has...
|
|
|
When Choosing Antibiotic Regimen, Location Is Key
Miami Beach, Fla.-A three-drug regimen consisting of double gram-negative coverage plus methicillin-resistant Staphylococcus aureus (MRSA) coverage is a must for increasing the success of proper initial empiric antibiotic selection, according to a study...
|
|
|
Antibiotic prescription patterns in hospitalized patients with nursing home-acquired pneumonia
Considerable research has increased our understanding of antibiotic prescribing practices in hospital settings when it comes to nosocomial pneumonia.Much less is known about the antibiotic prescribing patterns for hospitalized non-critically ill patients...
|
|
|
Genome mining in Amycolatopsis balhimycina for ferredoxins capable of supporting cytochrome P450 enzymes involved in glycopeptide antibiotic biosynthesis
Ferredoxins are required to supply electrons to the cytochrome P450 enzymes involved in cross-linking reactions during the biosynthesis of the glycopeptide antibiotics balhimycin and vancomycin.However, the biosynthetic gene clusters for these...
|
|
|
MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
Category: General News Font Size HAYWARD, Calif.and SHANGHAI, March 15 MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND)...
|
|
|
Akorn Reports 2009 Fourth Quarter and Year-End Financial Results
-Achieves Positive Fourth Quarter Cash Flow and Adjusted EBITDA- -Refocuses R&D efforts to Strengthen New Product Pipeline- LAKE FOREST, Ill.(BUSINESS WIRE) Akorn, Inc.(NASDAQ: AKRX), a niche generic pharmaceutical company, today reported financial...
|
|
|
Akorn Reports 2009 Fourth Quarter and Year-End Financial Results
LAKE FOREST, Ill.-- (BUSINESS WIRE) -- Akorn, Inc.(NASDAQ: AKRX), a niche generic pharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2009. Consolidated revenue for the fourth quarter of 2009 was $18...
|
|
|
Antiseptic Cloths Reduce Deadly Bacteria
(Ivanhoe Newswire) -- Bathing trauma patients daily using cloths containing the antiseptic chlorhexidine may be associated with a decreased rate of infection by methicillin-resistant Staphylococcus aureus (MRSA) and other difficult-to-treat bacteria....
|
|
|
::: MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
- MRX-I Targets Multi-Drug Resistant Gram Positive Infections - HAYWARD, Calif.and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has...
|
|
|
MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
MRX-I Targets Multi-Drug Resistant Gram Positive Infections - PR Newswire HAYWARD, Calif.and SHANGHAI, March 15 HAYWARD, Calif. and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next...
|
|
|
MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
- MRX-I Targets Multi-Drug Resistant Gram Positive Infections - PR Newswire HAYWARD, Calif.and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced...
|
